Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

3.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.1K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

931
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
931
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: Long-term Results of a Prospective Phase II Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Olecranon fractures: An old fixation device for a new surgical technique.

Injury·2024
Same author

Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial.

Clinical oncology (Royal College of Radiologists (Great Britain))·2021
Same author

The transCampus Metabolic Training Programme Explores the Link of SARS-CoV-2 Virus to Metabolic Disease.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2021
Same author

General practitioners' management of symptomatic uncomplicated diverticular disease of the colon by using rifaximin, a non-adsorbable antibiotic.

European review for medical and pharmacological sciences·2021
Same author

Impact of COVID-19 outbreak on emergency surgery and emergency department admissions: an Italian level 2 emergency department experience.

The British journal of surgery·2020

Related Experiment Video

Updated: Mar 30, 2026

A Murine Model of Vertical Sleeve Gastrectomy
06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.9K

Changes in insulin sensitivity and secretion after sleeve gastrectomy.

G Casella1, E Soricelli1, L Castagneto-Gissey1

  • 1Surgical Sciences Department, Medical School 'Sapienza' University, Rome, Italy.

The British Journal of Surgery
|November 10, 2015
PubMed
Summary

Sleeve gastrectomy significantly improves insulin sensitivity and reduces insulin secretion within six months. Glucagon-like peptide-1 (GLP-1) secretion is identified as the primary driver of these metabolic improvements.

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.6K
Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice
06:40

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice

Published on: February 10, 2023

2.2K

Related Experiment Videos

Last Updated: Mar 30, 2026

A Murine Model of Vertical Sleeve Gastrectomy
06:47

A Murine Model of Vertical Sleeve Gastrectomy

Published on: December 18, 2017

11.9K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.6K
Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice
06:40

Single-Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy Model in Mice

Published on: February 10, 2023

2.2K

Area of Science:

  • Metabolic Surgery
  • Endocrinology
  • Bariatric Procedures

Background:

  • Sleeve gastrectomy is a common bariatric procedure for obesity and associated comorbidities like diabetes.
  • The precise temporal effects of sleeve gastrectomy on insulin secretion and sensitivity remain incompletely understood.

Purpose of the Study:

  • To investigate the dynamic changes in whole-body insulin sensitivity and secretion following sleeve gastrectomy.
  • To assess the role of glucagon-like peptide-1 (GLP-1) in mediating these metabolic alterations.

Main Methods:

  • Utilized the euglycaemic hyperinsulinaemic clamp technique to measure whole-body insulin sensitivity.
  • Employed C-peptide deconvolution after an oral glucose tolerance test (OGTT) to quantify insulin secretion.
  • Monitored GLP-1 levels as a marker of incretin response post-OGTT.

Main Results:

  • Insulin sensitivity (M-value) significantly increased by 12 months post-surgery (P = 0.015).
  • Hepatic insulin resistance, assessed by HOMA-IR, markedly decreased (P < 0.001).
  • Total insulin secretion and GLP-1 levels showed significant reductions and increases, respectively (P = 0.011 and P < 0.001).

Conclusions:

  • Sleeve gastrectomy enhances insulin sensitivity and modulates insulin secretion within six months.
  • While body weight correlates with improved insulin sensitivity, GLP-1 secretion emerges as the principal factor driving these metabolic benefits.